 CAMBRIDGE, Mass., Feb. 12, 2021 GLOBE NEWSWIRE -- Jounce Therapeutics, Inc. NASDAQ: JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Luisa Salter-Cid, Ph.D., to its board of directors. 